This article has been updated from a previous version, which reported the value of the total public offering, rather than the value of Bruker BioSciences' net proceeds.
NEW YORK (GenomeWeb News) — Bruker BioSciences today gained $16.9 million in proceeds from a public offering of its common stock.
The company said it sold 2.53 million of its shares at $7.10 per share. An additional 9.4 million shares were sold by four stockholders. Bruker did not realize any of the net proceeds from the sale of stock by these shareholders.
Bruker plans to use the proceeds for corporate purposes, including repaying debt and for potential acquisitions.
Bruker said 1.6 million shares of this offering were sold after the underwriters exercised an over-allotment option.
Bear, Stearns & Co. and UBS Investment Bank are serving as joint bookrunning managers for the offering.